Vanda Pharmaceuticals Inc.
Calidad de datos: 100%
VNDA
Nasdaq
Manufacturing
Chemicals
$7.22
▼
$0.11
(-1.50%)
Cap. Mercado: 430.01 M
Precio
$7.28
Cap. Mercado
430.01 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—
Quick Summary
Puntos Clave
Revenue declined -5.30% annually over 5 years
Negative free cash flow of -110.44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 14.02%
Capital efficient — spends only 0.46% of revenue on capex
Crecimiento
Revenue Growth (5Y)
-5.30%
Below sector avg (1.82%)
Revenue (1Y)8.72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-46.30%
Above sector avg (-53.47%)
ROIC-24.21%
Net Margin-102.02%
Op. Margin-69.95%
Seguridad
Debt / Equity
N/A
Current Ratio3.12
Interest CoverageN/A
Valoración
PE (TTM)
-1.95
Below sector avg (-1.48)
P/B Ratio0.92
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -2.0 | -1.5 |
| P/B | 0.9 | 1.6 |
| ROE % | -46.3 | -53.5 |
| Net Margin % | -102.0 | -41.5 |
| Rev Growth 5Y % | -5.3 | 1.8 |
| D/E | — | 0.3 |
Precio Objetivo de Analistas
5 analistas
Buy
Actual
$7.22
Objetivo
$15.50
$7.50
$17.00
$24.00
Pronóstico
EPS Futuro
-$0.79
Ingresos Est.
353.27 M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
-$0.79
-$1.23 – -$0.43
|
353.27 M | 5 |
| FY2026 |
-$2.24
-$2.79 – -$1.65
|
257.11 M | 5 |
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| 2026 Q2 |
-$0.57
-$0.68 – -$0.51
|
61.21 M | 5 |
| 2026 Q1 |
-$0.69
-$0.94 – -$0.49
|
55.04 M | 5 |
Sorpresas de Ganancias
Últimos 4 trimestres
| Trimestre | EPS Est. | EPS Real | Sorpresa |
|---|---|---|---|
| Q42025 | -$1.33 | -$2.39 | -80.4% |
| Q32025 | -$0.45 | -$0.38 | +16.2% |
| Q22025 | -$0.36 | -$0.46 | -29.0% |
| Q12025 | -$0.60 | -$0.50 | +16.2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.72% | Revenue Growth (3Y) | 5.92% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -5.30% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 216.11 M | Net Income (TTM) | -220.47 M |
| ROE | -46.30% | ROA | -35.97% |
| Gross Margin | N/A | Operating Margin | -69.95% |
| Net Margin | -102.02% | Free Cash Flow (TTM) | -110.44 M |
| ROIC | -24.21% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.12 |
| Interest Coverage | N/A | Asset Turnover | 0.35 |
| Working Capital | 249.63 M | Tangible Book Value | 357.16 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.95 | Forward P/E | N/A |
| P/B Ratio | 0.92 | P/S Ratio | 1.99 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -25.68% | ||
| Market Cap | 430.01 M | Enterprise Value | 359.99 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.74 | Revenue / Share | 3.66 |
| FCF / Share | -1.87 | OCF / Share | -1.85 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.46% | FCF Conversion | 50.09% |
| SBC-Adj. FCF | -120.63 M | Growth Momentum | 14.02 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 216.11 M | 198.77 M | 192.64 M | 254.38 M | 268.68 M |
| Net Income | -220.47 M | -18.90 M | 2.51 M | 6.28 M | 33.15 M |
| EPS (Diluted) | -3.74 | -0.33 | 0.04 | 0.11 | 0.58 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -151.17 M | -40.66 M | -13.95 M | 6.33 M | 42.17 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 109.27 M | 74.43 M | 76.82 M | 85.77 M | 75.36 M |
| SG&A Expenses | 237.95 M | 146.41 M | 112.88 M | 136.49 M | 124.05 M |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 81.83 M | -4.02 M | 3.83 M | 5.03 M | 9.21 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 488.95 M | 656.20 M | 648.44 M | 634.25 M | 593.79 M |
| Total Liabilities | 161.76 M | 117.66 M | 103.53 M | 107.05 M | 88.86 M |
| Shareholders' Equity | 327.19 M | 538.55 M | 544.91 M | 527.20 M | 504.93 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 84.85 M | 102.32 M | 135.82 M | 135.03 M | 52.07 M |
| Current Assets | 347.26 M | 438.89 M | 432.95 M | 519.29 M | 478.30 M |
| Current Liabilities | 145.16 M | 99.98 M | 87.70 M | 91.44 M | 74.42 M |
{"event":"ticker_viewed","properties":{"ticker":"VNDA","listing_kind":"stock","pathname":"/stocks/vnda","exchange":"Nasdaq","country":"US"}}
